Summary
The history of the development of influenza virus vaccine is traced from its origin with experimental studies of influenza virus in ferrets and mice and the first trials in man. Knowledge of the basis of immunity to the viruses in experimental animals and in man has grown steadily over the years and has been essential to successful immunization. Virus variation affecting the surface antigens of the virus is seen as the principal obstacle to the application of vaccines in man. So significant are the changes occurring during antigenic drift that former concepts of a polyvalent vaccine cannot provide a solution of the problem of the composition of vaccines. Disrupted virus vaccines appear to provide the answer to the prevention of vaccine reactions.
EFFORTS to develop an ideal influenza vaccine stem basically from studies carried out at Mill Hill more than 4 decades ago. Smith, Andrewes and Laidlaw (1933) initiated the quest in 1933 by isolating, identifying, and characterizing one of the causal agents of epidemic influenza. Convalescent ferrets were found to be immune to challenge and their sera as well as those of recovered patients exhibited neutralizing activity. Clearly the virus could be contained.
In 1934, Andrewes, Laidlaw and Smith (1934) (1935) reported that hyperimmune horse serum or its pseudo-globulin fraction conferred some degree of passive immunity when given to mice, before or even after challenge. In a companion paper, Smith, Andrewes and Laidlaw (1935) demonstrated that ferrets developed neutralizing serum antibodies after subcutaneous injection of live or formalin-inactivated virus suspensions.
Nevertheless, by clinical criteria, these animals were fully susceptible when given virus intranasally without benefit of anaesthesia. Now Shope had written that prior administration of live virus subcutaneously prevented the pneumonia which develops after intranasal administration of swine virus to anaesthetized ferrets. Further, he had earlier published that intramuscular injection of active swine virus conferred firm immunity to pigs challenged via the respiratory route (Shope, 1932) . Smith et al. (1935) found it 'inconceivable that possession of neutralizing antibodies in the circulation should confer no sort of benefit'. They extended Shope' s vaccine experiments in anaesthetized ferrets, using active and formalin-treated suspensions of swine and human strains. In every case vaccination resulted in a partial immunity sufficient to protect the lung from virus attack. Moreover, it was demonstrated that the waning immunity of ferrets held 7-10 months after primary infection could be reinforced to solid immunity by a single subcutaneous dose. Demonstration of partial protection of mice given repeated subcutaneous or intradermal injections of active virus, and further information on the antigenic relationships and differences between swine and human influenza strains were additional components of this remarkably informative paper.
Several portions of the discussion in the paper by Smith et al. (1935) Independent contemporary studies carried out by Frances (1934a, b; and by Francis and Magill (1935a) and in New York in 2 (Francis and Magill, 1935a) Koen's (1919) view regarding the origin of swine influenza, with information on antigenic dissimilarities between swine and human influenza strains, and differences in the age distribution of antibodies to these viruses in human sera Burnet (1937) and by Andrewes (1937 In an accompanying paper, Smith and Andrewes (1938) noted that the use of a 'non-specific master strain might be expected to have more chances of success because it would evoke an immunologic response of wider range'. Less enthusiasm was expressed for employment of polyvalent preparations owing to the dilution of particularly important components. Obviously, concern about strain composition of influenza vaccine is not a recent development.
Almost in parallel, experience with use of influenza vaccines in man was accumulating rapidly. Francis and Magill (1935b) described cultivation of influenza virus in minced embryo tissue culture and in 1936 gave a preliminary report on vaccination of human subjects with active tissue culture virus . A more detailed report followed (Francis and Magill, 1937) . Volunteers were screened to ensure that their pre-vaccination sera possessed the least protective power against a 10% suspension of mouse-adapted virus. At weekly intervals, 11 individuals received subcutaneously 3 doses of culture virus contained in 05 cm3, 1-0cm3 and 1.0 cm3 respectively. Two to 3 weeks later, an additional dose of 2-0 cm3 was given by the same route. A second group of 5 subjects received subcutaneously weekly doses of 1.0 cm3, 1-0 cm3 and 2-0 cm3. A third group of 7 subjects was inoculated intradermally with 3 weekly doses of 0-5 cm3 of culture virus. Samples of blood were obtained at each vaccination and 10 days after the last. Obviously, questions on optimal dose, route, and schedule were being probed.
The findings were encouraging. Vaccination uniformly increased the capacity of sera to neutralize human influenza virus, as judged by mouseprotection tests. The rise in antibodies occurred abruptly in the second week and was maintained for 2 months. At 5 months a modest decline in antibody was noted. Levels attained after vaccination were comparable to those found after natural infection. The results in the group of individuals receiving vaccine intradermally appeared to follow the same course as in those inoculated subcutaneously, though at a lower level. The vaccine was well tolerated. Fever was not encountered. Local reactions after subcutaneous inoculation were cited as inconstant and extremely mild. Intradermal administration produced more erythema.
At the same time, Stokes et al. (1937) were also testing live influenza vaccines. They used Berkefeld filtrates of 10% suspensions of infected lungs. One hundred and thirty-eight males from various institutions were vaccinated intramuscularly with swine virus, 110 subjects received the PR8 strain. A large group of non-inoculated controls was identified. The results are difficult to evaluate. Only 31% of the PR8 vaccinated subjects exhibited a serum neutralizing antibody increase. Vaccination was started after influenza had first become epidemic in the area. It was later shown that 1936 was a period of influenza B prevalence in the United States (Francis, 1940a Nevertheless, the failure to confirm vaccine efficacy was sobering.
During the next 2 years, field trials of inactivated vaccines continued to yield inconsistent results. A beneficial effect was described in 2 studies (Horsfall et al., 1941; Brown et al., 1941) ; no benefit was noted in 3 others (Taylor and Dregus, 1940. Dalldorf, Whitney and Ruskin, 1941; Siegel et al.' 1942a, b) . Possible explanations for certain of the' inconsistencies were suggested in a later review (Francis, 1950 (1933) . Total rapid destruction of the respiratory epithelium with evolution of total repair through stages of transitional and squamous to the final stratified columnar epithelium was described in detail (Francis and Stuart-Harris, 1938a ). In the second, ' The resistance of regenerating respiratory epithelium to reinfection and to physiochemical injury', the immature transitional type of epithelium which covers the respiratory area on the seventh or eighth day after infection, was shown to be resistant to reinfection with influenza virus and to severe physiochemical injury (Stuart-Harris and Francis, 1938) . The third, 'Histologic and serologic observations on ferrets receiving repeated inoculations of epidemic influenza virus', called attention to the role of serum antibody in limiting the extent of cellular injury and the existence of an exaggerated reparative capacity in the virus-conditioned animal. The degree of immunity found in reinfection was considered the product of serological immunity and the rate of tissue repair (Francis and Stuart-Harris, 1938b) .
Obviously, cellular as well as humoral factors were involved; yet more information was needed. Discrepancies between levels of serum antibody found in certain individuals and their resistance to natural infection had been noted in a number of the early publications. The results of studies on the relation between serum antibody and the clinical and histological responses of challenged ferrets also made it clear that circulating antibodies did not fully control susceptibility of the upper respiratory tract. Francis (1940b) focused attention upon the significance of local humoral factors. Nasal secretions of a high proportion of human subjects were shown to contain neutralizing antibodies, and the concentration of these, while low or undetectable in acute specimens, was found to be substantially increased following an attack of influenza. Intercurrent attacks of the 'common cold' had no such effect (Francis and Brightman, 1941) . Of primary importance to the question of prevention of influenza by vaccination was the demonstration by Francis et al. (1943) that subcutaneous administration of active or inactive virus was followed promptly by a substantial increase in nasal as well as serum antibody. A model for natural or vaccine induced resistance to influenza could now be discerned. Cellular and humoral factors conditioned by prior antigenic experience conferred the primary defence at the portal of entry. Serum antibody, available to respiratory membranes by transudation, constituted an important secondary resource that limited the extent of injury.
At that time then, there was a model of how influenza vaccines could or should work, but no explanation of why they did not, at least consistently.
Because of the overall correlation found between levels of serum antibody and resistance to disease (Hoyle and Fairbrother, 1937) , one possible explanation for the failures was that they were the consequence of employment of weak vaccines incapable of stimulating antibody levels to uniformly adequate heights. In short order, a series of technical developments made it possible to test this hypothesis. Some time before, Smith (1935) and, independently, Burnet (1935) (Hirst, 1942; showed by the use of active allantoic fluid virus and centrifuged concentrates that the haemagglutination inhibiting antibody response of human subjects was increased as the dose of subcutaneous vaccine was increased. In a later study, Hirst, Richard and Whitman (1942) (Francis, 1958; Davenport, Lennette and Meiklejohn, 1970 (Francis, 1953; Francis and Maassab, 1965a; Davenport, 1973 (Tauraso, O'Brien and Seligman, 1969) .
However, because viral aggregates, viral filaments and viral fragments may react with erythrocytes as if each were a single virus particle, CCA titres can be unreliable indices of antigen mass, depending upon the mixture tested. It is hoped that an improved single-radial-immunodiffusion technique devised by Wood et al. (1977) (Tauraso et al., 1969) .
Questions on the optimal route of administration are by this time fairly well resolved. The larger dose that can be administered subcutaneously generally performs as a stronger stimulus than does the smaller, intradermal one commonly used (Davenport and Hennessy, 1960) . Appleby, Himmelweit and Stuart-Harris (1951) contributed important data to this point. The application of intranasal sprays containing large amounts of inactivated viruses has not proved as beneficial as the routine use of vaccine subcutaneously when evaluated in field trials (Waldman et al., 1969) or in volunteer studies (Beare et al., 1969 (Francis, 1952; Davenport and Hennessy, 1957 (Francis and Maassab, 1965b Beare (1975) and by Murphy, Spring and Channock (1976) .
It is surely evident to all that, despite enormous progress along a difficult road, we do not yet have the ideal influenza vaccine. We only have very effective ones that are being under-utilized at present (StuartHarris, 1970 ). Nevertheless, it should be noted that the beginnings were brilliant, the coursing has been courageous and, whilst the present seems imperfect, the future fascinates because of the remaining challeiges. Sir Charles Stuart-Harris has been and is certain to continue to be a prime mover in the ultimate search for the ideal influenza vaccine. BURNET, F.M. (1941) 
